Global Immunotherapy Drugs Market - Segmented by Type of Drug, Therapy Area, End-User and Geography - Growth, Trends and Forecast (2018 - 2023)

  • ID: 4557820
  • Report
  • Region: Global
  • 110 pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2018
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • MORE
The global immunotherapy drugs market is expected to register a CAGR of nearly 13.0% during the forecast period, 2018-2023. The immunotherapy drugs market is primarily expected to rise due to rising prevalence of cancer and infectious diseases as these therapies are used to improve the human immunity to fight against diseases. With a well-established healthcare infrastructure and rising demand for advanced therapies, makes the North America region to dominate the immunotherapy drugs market.

Increasing Global Prevalence of Chronic Diseases and Lifestyle Disorders

The increasing global prevalence of chronic diseases and lifestyle disorders is one of the major factors propelling this market. These diseases majorly includes cardiovascular diseases, cancer, stroke, infectious diseases, lung disorders, diabetes, chronic kidney diseases and liver diseases. According to chronic diseases prevention and health promotion, in 2015, more than 85% of the US annual healthcare expenditures was spent on people with chronic diseases and mental health condition. Other factors associated with lifestyle disorders such as obesity, changing lifestyle globally as well as smoking and eating habits are vital factors aggravating the chronic diseases. All these factors raise the demand for immunotherapy drugs market.

Other factors driving this market are rising adoption of targeted therapies over traditional therapies, the emergence of biosimilars and rising demand for monoclonal antibodies.

High Cost of Immunotherapy Treatment

The immunotherapies are expensive and that is one of the primary reasons declining this market. Immunotherapies are often covered by the health insurance companies but still, a major part of its costs are paid from the patients’ packets. In the US, it is estimated that the cost reaches above USD 1.0 million per year and when combined with other drugs, it is above USD 2.0 million per year. In the emerging markets such as India, the cost of one immunotherapy is in the range of 1-3 lakhs and it continues for a period of 3-6 months. Therefore, it is not easily affordable globally.

Other factors affecting this market is the higher attrition rate in the product development cycle.

US is Expected to Have the Largest Share in the Forecast Period

In North America, the US is expected to have the largest market share related to immunotherapy market. The factors such as increased awareness among people for the early detection of diseases, better reimbursement policies, healthcare expenditure with better infrastructure and rising prevalence of chronic and lifestyle disorders are primary factors raising the immunotherapy market in this country. The Asia Pacific has a large diversified patient pool with growing economies and rising awareness among people regarding chronic and infectious diseases which is expected to raise the immunotherapy market at the highest rate among the global regions

Key Developments in the Market
  • March, 2018 - Inovio collaborated with ApolloBio Corp, and provided exclusive right to develop, manufacture and commercialize VGX-3100, a DNA immunotherapy, in greater China.
  • March, 2018 - Novartis collaborated with Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute for developing next generation biomaterials systems to deliver immune-oncology therapies.
Major Players: ABBVIE INC, AMGEN INC, ASTRAZENECA, BRISTOL-MYERS SQUIBB, F. HOFFMANN-LA ROCHE AG, GLAXOSMITHKLINE PLC, JOHNSON & JOHNSON, MERCK & CO., INC, NOVARTIS AG, and UBIVAC, amongst others.

Reasons to Purchase this Report
  • Current and future of the immunotherapy drugs outlook in the developed and emerging markets
  • Analyzing various perspectives of the market with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness fastest growth during the forecast period
  • Identify the latest developments, market shares and strategies employed by the major market players.
  • 3 months analyst support along with the Market Estimate sheet (in excel).
Customization of the Report

This report can be customized to meet your requirements. Please contact us for more information.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry

6. Market Dynamics
6.1 Market Drivers
6.1.1 Rising Adoption of Targeted Therapy over Traditional Therapy
6.1.2 Emergence of Biosimilars
6.1.3 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
6.1.4 Rising Demand for Monoclonal Antibodies
6.2 Market Restraints
6.2.1 High Cost of Immunotherapy Treatment
6.2.2 High Attrition Rate in the Product Development Cycle
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Type of Drug
7.1.1 Monoclonal Antibodies
7.1.2 Vaccines
7.1.2.1 Preventive Vaccines
7.1.2.2 Therapeutic Vaccines
7.1.3 Checkpoint Inhibitors
7.1.4 Interferons Alpha & Beta
7.1.5 Interleukins
7.1.6 Others
7.2 By Therapy Area
7.2.1 Cancer
7.2.2 Autoimmune and Inflammatory Diseases
7.2.3 Infectious Diseases
7.2.4 Others
7.3 By End-user
7.3.1 Hospitals/Clinics
7.3.2 Cancer Research Centers
7.3.3 Others
7.4 By Geography
7.4.1 North America
7.4.1.1 US
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 UK
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America

8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches

9. Key Players
9.1 AbbVie Inc
9.2 Amgen Inc
9.3 AstraZeneca
9.4 Bristol-Myers Squibb
9.5 F. Hoffmann-La Roche AG
9.6 GlaxoSmithKline plc
9.7 Johnson & Johnson
9.8 Merck & Co., Inc
9.9 Novartis AG
9.10 UbiVac
*List Not Exhaustive

10. Future Market Outlook
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc
  • Novartis AG and UbiVac
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll